WaveMan
WaveMan · Company
APUS · Apimeds Pharmaceuticals Us, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

APUS Apimeds Pharmaceuticals US (APUS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001894525
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
3
13F, latest reported quarter

Apimeds Pharmaceuticals US insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Apimeds Pharmaceuticals US, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Kim Christopher
Chairman and CMO
BUY
2025-05-15 SECtraded 2025-05-14
7,730
$14.4K
-82.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 13, 2025.
  • The trade is 28.1% of the 27,500 shares held after it.
  • 2 other insiders bought within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CMO Kim Christopher bought about $14.4K of APUS on May 14, 2025; 2 other insiders bought within 30 days and 3 funds added in the latest 13F quarter.
Kim Christopher
Chairman and CMO
BUY
2025-05-15 SECtraded 2025-05-13
19,770
$36.0K
-82.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 19,770 shares held after it.
  • 2 other insiders bought within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CMO Kim Christopher bought about $36.0K of APUS on May 13, 2025; 2 other insiders bought within 30 days and 3 funds added in the latest 13F quarter.
Koo Jakap
Director
BUY
2025-05-14 SECtraded 2025-05-12
28,500
$56.7K
-82.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 4.4% of the 643,885 shares held after it.
  • 2 other insiders bought within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Koo Jakap bought about $56.7K of APUS on May 12, 2025, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 3 funds added in the latest 13F quarter.
Inscobee Inc.
BUY
2025-05-14 SECtraded 2025-05-12
500,000
$2.0M
-82.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 25.2% of the 1,984,616 shares held after it.
  • 2 other insiders bought within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Inscobee Inc. bought about $2.0M of APUS on May 12, 2025, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 3 funds added in the latest 13F quarter.
4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
3 funds bought in last quarter
below 99% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.8% of shares outstanding short · 1.0 days to cover · settled 2026-10-15
more than 51% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch APUS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-82.4%12M
-91%-19%+53%+125%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns APUS: institutional holders (13F)

13F holdings, latest reported quarter
Hemenway Trust Co LLC
274,000 sh
$246.6K
VANGUARD CAPITAL MANAGEMENT LLC
63,654 sh
$57.3K
GEODE CAPITAL MANAGEMENT, LLC
35,114 sh
$31.6K
VANGUARD FIDUCIARY TRUST CO
24,039 sh
$21.6K
JANE STREET GROUP, LLC
15,993 sh
$14.4K

Congress trades in APUS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

APUS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

APUS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$38.5K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$46.5K position · as of 2026-06-30
0.0%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND
$10.8K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$13.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 3 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

APUS financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$13.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
current debt only, 2024-07-19 (23 months older than the period end); equity 2026-06-30
Cash flow to debt
-663.96x
TTM operating cash flow over current debt only, 2024-07-19 (23 months older than the period end)
Return on equity
-100.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-84.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-47.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$4.3M
market value at close 2026-10-27 on 2026-08-12 shares, plus current debt only, 2024-07-19 (23 months older than the period end), minus cash 2026-06-30
FCF yield
-289.7%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Operating income-$11.9M-$1.3M-$747.4K
Net income-$6.0M-$1.4M-$777.7K
EPS (diluted)-0.55-0.18-0.17
Operating cash flow-$8.9M-$733.5K-$627.8K
Cash$1.6M$3.5K$410.5K
SEC XBRL, fiscal years, as known on 2026-10-28

APUS Stock Sonar score 4/7 axes

Find similar shapesCompare

APUS ranks highest on risk and compliance (59th percentile) and financial health (44th), and lowest on institutional and government (1st), among Pharma & Biotech peers.

Profitability
38
Inputs
  • Return on equity-100.1% · 33 pct, sector of 545
  • Return on assets-84.2% · 28 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-47.0% · 53 pct, sector of 576
Financial health
44
Inputs
  • Debt to equity0.00x · 87 pct, sector of 352
  • Cash flow to debt-663.96x · 2 pct, sector of 371
Institutional and government
1
Inputs
  • Funds adding, latest quarter3 · 1 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
59
Inputs
  • Short interest, % of shares outstanding (no float on file)+4.8% · 59 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Growth, Insider conviction, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies